Market Insights

Latest research, educational guides, and news from the world of institutional investing.

News

Abbott Cut Its 2026 EPS View After the Exact Sciences Deal, but the $168B Holder Base Barely Moved

Abbott's first-quarter 2026 report was good enough on revenue and still weak enough on guidance to send the stock lower. But the institutional picture argues this was a valuation reset, not a confidence break: 3,244 institutions still held about $168.1 billion of ABT at year-end, and the top five holders all added modestly quarter over quarter while JPMorgan was the main visible exception.

By Alex Rivera
News

Netflix Fell After Earnings, but the $329B Institutional Base Still Looks Built to Buy the Dip

Netflix shares sold off after its April 16, 2026 earnings report because guidance did not move higher and the Reed Hastings transition revived governance questions. But the ownership data is less fragile than the price action suggests: 3,485 institutions still held about $329.5 billion of NFLX at year-end, and the top four passive giants were still broadly steady once you adjust for Netflix's 10-for-1 stock split.

By Alex Rivera
News

Cerebras Files to IPO as Nvidia's Biggest Passive Holder Quietly Cut More Than a Billion Shares

Cerebras Systems filed its US IPO paperwork just as the most important institutional signal on Nvidia flipped bearish: Vanguard, which held 9.32% of NVDA (2.27 billion shares) in late January 2026, filed a Schedule 13G/A in March showing ownership had dropped below the 5% reporting threshold. That's a reduction of at least 1.05 billion shares in two months — the single largest mega-cap position unwind visible in our 13D/G data — and it happened just before a credible AI-chip rival filed to go public.

By Alex Rivera
News

Lilly Just Got the FDA Nod on Its Weight-Loss Pill — But Vanguard Had Already Cut Below 5% and Wall Street's Bigger Holders Were Quietly Trimming

Eli Lilly's oral weight-loss pill orforglipron cleared a key FDA hurdle — a potentially watershed moment for GLP-1 therapeutics. But the institutional ownership tells a less jubilant story: Vanguard filed a sub-5% threshold disclosure on LLY in March 2026, after being at 8.55% just five months earlier, while Lilly's own family endowment trimmed its stake from 10.1% to 9.8%. The question now: do the biggest holders re-enter on the FDA catalyst, or was the position cut structurally permanent?

By Alex Rivera
News

Court Halts Nexstar's $6.2B Tegna Takeover — But the Institutional Money Was Already Quietly Exiting

A federal judge temporarily blocked Nexstar's $6.2 billion merger with Tegna over antitrust concerns, freezing one of 2026's largest media consolidation bets. But the real story is what's happening in the institutional ownership: BlackRock and Vanguard — the top holders of BOTH companies — had already been trimming positions before the injunction, suggesting smart money saw the regulatory risk coming.

By Alex Rivera
PreviousPage 2 of 39Next